awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q42385052-0B05BED2-848E-4CE7-AC72-068FA48DF579
Q42385052-0B05BED2-848E-4CE7-AC72-068FA48DF579
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42385052-0B05BED2-848E-4CE7-AC72-068FA48DF579
The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
P2860
Q42385052-0B05BED2-848E-4CE7-AC72-068FA48DF579
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42385052-0B05BED2-848E-4CE7-AC72-068FA48DF579
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
6b8294127b54b1fd1bfa999328ea5750c1c1f55a
P2860
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.